Older adults: should the paradigm shift from standard therapy?

Area of Science:

• Hematology
• Geriatric Oncology
• Clinical Therapeutics

Background:

• Acute myelogenous leukemia (AML) disproportionately affects older adults.
• Standard treatment options for AML in older adults include the "3+7" regimen, low-dose cytarabine (ara-C), investigational therapy, or palliative care.
• Many investigational therapies exclude older patients with poor performance status or organ dysfunction.

Purpose of the Study:

• To analyze treatment strategies for older adults (age 60+) diagnosed with acute myelogenous leukemia.
• To evaluate the efficacy and applicability of standard versus investigational therapies in this demographic.
• To identify patient subgroups that may benefit from specific treatment approaches.

Main Methods:

• Review of existing treatment guidelines and clinical trial exclusion criteria for AML in older adults.
• Analysis of patient stratification factors, including performance status (Zubrod score) and organ function (bilirubin, creatinine levels).
• Comparison of outcomes for patients receiving standard therapy versus investigational agents.

Main Results:

• Standard therapy ("3+7" or low-dose ara-C) offers limited benefit for many older AML patients.
• Investigational treatments often exclude a significant portion (10-20%) of older patients with poor prognostic indicators.
• Patient stratification is crucial, as some older adults may benefit from standard therapy, while others require investigational options.

Conclusions:

• Treatment decisions for older adults with AML must be individualized based on performance status and organ function.
• A significant subset of older AML patients excluded from clinical trials may still be candidates for investigational therapy.
• Further research is needed to optimize treatment strategies for all older adults with AML, regardless of their prognostic factors.